Trends in dermatology eponyms.

Background: Eponyms are ubiquitous in dermatology; however, their usage trends have not been studied.

Objective: To characterize the usage of eponyms in dermatology from 1880 to 2020.

Methods: Candidate eponyms were collected from a textbook and an online resource.

A Biopython-based method for comprehensively searching for eponyms in Pubmed.

Eponyms are common in medicine; however, their usage has varied between specialties and over time. A search of specific eponyms will reveal the frequency of usage within a medical specialty. While usage of eponyms can be studied by searching PubMed, manual searching can be time-consuming.

Dry Reagent Tests in the 1880s-Dr Pavy's Pellets and Dr Oliver's Papers.

Background: In the 1880s, concern over the inconvenience of hazardous chemical solutions used for bedside urinalysis sparked an interest in the development of dry reagents for a range of common urine tests.

Content: This article examines the history of Dr Pavy's Pellets and Dr Oliver's Papers, 2 different dry reagent systems developed in the 1880s for bedside urine testing. It sets these developments in the context of the earlier dry chemistry work (e.

Eponyms in clinical chemistry.

Background: Eponyms are commonly used in medicine, but there are no specific studies of the use of eponyms in clinical chemistry.

Methods: Clinical chemistry eponyms were manually collected from books, review articles and journal articles from 1847 through 2020. Eponym usage was examined by searching titles and abstracts in PubMed.

Artificial Intelligence-Powered Search Tools and Resources in the Fight Against COVID-19.

Emerging technologies are set to play an important role in our response to the COVID-19 pandemic. This paper explores three prominent initiatives: COVID-19 focused datasets (e.g.

Key questions about the future of laboratory medicine in the next decade of the 21st century: A report from the IFCC-Emerging Technologies Division.

This review advances the discussion about the future of laboratory medicine in the 2020s. In five major topic areas: 1. the "big picture" of healthcare; 2.

History of disruptions in laboratory medicine: what have we learned from predictions?

Predictions about the future of laboratory medicine have had a mixed success, and in some instances they have been overambitious and incorrectly assessed the future impact of emerging technologies. Current predictions suggest a more highly automated and connected future for diagnostic testing. The central laboratory of the future may be dominated by more robotics and more connectivity in order to take advantage of the benefits of the Internet of Things and artificial intelligence (AI)-based systems (e.

Current and Emerging Trends in Point-of-Care Technology and Strategies for Clinical Validation and Implementation.

Background: Point-of-care technology (POCT) provides actionable information at the site of care to allow rapid clinical decision-making. With healthcare emphasis shifting toward precision medicine, population health, and chronic disease management, the potential impact of POCT continues to grow, and several prominent POCT trends have emerged or strengthened in the last decade.

Content: This review summarizes current and emerging trends in POCT, including technologies approved or cleared by the Food and Drug Administration or in development.

Chemiluminescence.

Radioactive reagents have been gradually replaced by nonisotopic reagents for some tasks in molecular biology. Concern over laboratory safety and the economic and environmental aspects of radioactive waste disposal have been key factors in this change. Generally, the new nonisotopic systems have improved in terms of analytical sensitivity and the time required to obtain a result.

Emerging and Disruptive Technologies.

Several emerging or disruptive technologies can be identified that might, at some point in the future, displace established laboratory medicine technologies and practices. These include increased automation in the form of robots, 3-D printing, technology convergence (e.g.

Quality assurance for multiplexed assays - how can it be achieved?

Multiplexed assays are now a common form of analysis in routine clinical and research laboratories. Assuring the quality of this type of complex, massively-parallel testing poses challenges not encountered in the traditional single-plex assay. A range of quality assurance measures is implemented at different stages in a multiplex assay, beginning in the manufacturing process, and the ensuing analytical and data interpretation stages.

Nanostructured luminescently labeled nucleic acids.

Important and emerging trends at the interface of luminescence, nucleic acids and nanotechnology are: (i) the conventional luminescence labeling of nucleic acid nanostructures (e.g. DNA tetrahedron); (ii) the labeling of bulk nucleic acids (e.

Clinical exome performance for reporting secondary genetic findings.

Background: Reporting clinically actionable incidental genetic findings in the course of clinical exome testing is recommended by the American College of Medical Genetics and Genomics (ACMG). However, the performance of clinical exome methods for reporting small subsets of genes has not been previously reported.

Methods: In this study, 57 exome data sets performed as clinical (n = 12) or research (n = 45) tests were retrospectively analyzed.